RSV In Vitro

Respiratory syncytial virus (RSV) is a major human pathogen causing mild to severe respiratory infec- tions. RSV infection is particularly serious in infants and young children and causes more than 125,000 hospitalizations and 400 deaths among infants annually. Vaccine and treatment options are limited. RSV induced pathology includes damage from both the virus and the host immune response.

In vitro studies are used to test drug candidates for activity against RSV. IBT uses the RSV A2 strain in the well-established Vero and HEp-2 cell lines.

  • HEp-2 cells infected and CPE detected using a standard crystal violet staining
  • Boxed point is excluded from the curve fitting of CPE assay  due to the interference from cytotoxicity

  • RSV viral RNA copies in yield assay of test article by RT-qPCR. Control is virus only.
Back To Top
Fig. 1 Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain). Inoculum 1xLD90=1.0E+05 PFU/mouse
Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain) 1.0E+05 PFU/mouse
Survival and weight change in BALB/c mice challenged with INFV A/ Texas/36/91 (H1N1) and treated with antiviral Osletamivir Phosphate (Tamiflu)
Lung viral load and Survival (30 % weight loss cut-off) in BALB/c mice challenged with INFV H3N2 A/HK/1/68.